CLChun-Ling Luo

Chun-Ling Luo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chun-Ling Luo has a total of 124 co-authors. Here are the top co-authors by number of shared publications:

  • Jin-Xin Bei

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

    13 shared publications
  • Pan-Pan Wei

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China

    11 shared publications
  • Shuai He

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

    9 shared publications
  • Ya-Qing Zhou

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

    8 shared publications
  • Shu-Qiang Liu

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China

    7 shared publications
  • Yang Liu

    State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, PR China

    6 shared publications

Latest Publications

  • Open Access

    Epstein-Barr virus drives nasopharyngeal carcinoma metastasis via RNA m5C modification of ICAM-1 mediated by NSUN2 and YBX3

    by Xiu-Zhi Wang, Jia-Xin Jiang, Yi-Qi Li, Yang Liu, Shuang-Yan Ye, Wei Liu, Dong-Mei Chi, Shuai He, Pan-Pan Wei, Hui-Qiang Huang, et al.

    Epstein-Barr virus (EBV) is a critical epigenetic regulator in nasopharyngeal carcinoma (NPC) pathogenesis, primarily through well-established mechanisms involving DNA methylation and histone modifications. However, the contribution of RNA modifications, especially RNA 5-methylcytosine (m 5 C), to EBV-driven NPC progression remains largely unclear. Here, we performed RNA bisulfite sequencing (RNA-Bis-seq) on NPC cells and observed a global elevation in RNA m 5 C levels following EBV infection. Notably, EBV infection upregulated NSUN2, a known RNA m 5 C methyltransferase (“writer”), through LMP1-mediated activation of the NF-κB signaling pathway, leading to RNA m 5 C elevation. Functional assays confirmed that NSUN2 significantly enhances NPC cell migration and metastasis through its RNA m⁵C catalytic activity. Furthermore, we identified YBX3 as a novel RNA m⁵C-binding protein (“reader”) that was simultaneously upregulated upon EBV infection. Mechanistically, NSUN2 catalyzed m 5 C modification on ICAM-1. Subsequently, YBX3 specifically recognized the modified site, recruiting PABPC1 through interacting with its cold shock domain and thereby enhancing ICAM-1 translation. Consistently, ICAM-1 overexpression effectively rescued the metastasis defects induced by NSUN2 knockdown. Additionally, we observed significant positive correlations among NSUN2, YBX3, and ICAM-1 expression levels in NPC tissues, with their expression strongly associated with tumor progression and poor prognosis. Together, our findings reveal the crucial role of RNA m 5 C modification in EBV-associated NPC progression, delineate the LMP1/NSUN2/YBX3/ICAM-1 signaling cascade, and suggest this regulatory axis as a potential therapeutic target for NPC.


  • Open Access

    SDC1 + CAFs secreting CTGF drive tumour metastasis via FGFR3 signalling in cancers

    by Guan-Feng Gao, Zhao-Hui Ruan, Shi-Bo Zhang, Shuai He, Yi-Qi Li, Jin-Li Lyu, Yang Liu, Xing-Liang Tan, Yan-Jun Wang, Zhuo-Wei Liu, et al.

    Background: Cancer-associated fibroblasts (CAFs) are key stromal components of the tumour microenvironment (TME) that profoundly influence tumour progression. However, CAFs exhibit pronounced phenotypic and functional heterogeneity, and whether conserved CAF subtypes with shared functional hallmarks exist across different cancer types remains unclear. Objective: We sought to uncover universal CAF subtypes that transcend tumour origins, defining their core molecular signatures and pro-tumorigenic functions within the TME. Design: We constructed a pan-cancer CAF atlas through single-cell transcriptomic analysis of 554 specimens across 14 cancer types. To validate the findings, we performed further functional analyses, including in vitro migration and invasion assays, in vivo lymphatic metastasis models and mechanistic studies focusing on candidate signalling pathways. Results: We identified a conserved syndecan 1 (SDC1) + CAF subset associated with advanced tumour stage and poor outcomes. These CAFs enhanced tumour cell migration and invasion in vitro and promoted lymphatic metastasis in vivo. This effect is mediated through connective tissue growth factor (CTGF) secretion, which activates fibroblast growth factor receptor 3 (FGFR3) signalling in tumour cells to induce epithelial-mesenchymal transition (EMT). Blocking CTGF or FGFR3 signalling abrogated these effects. We also found that kruppel like factor 6 (KLF6) directly regulates CTGF in SDC1 + CAFs, establishing a complete KLF6-CTGF-FGFR3 metastatic axis. Conclusions: Our study establishes SDC1 + CAFs as a universal, metastasis-promoting CAF subset across multiple cancer types and uncovers a novel KLF6-CTGF-FGFR3 axis that drives EMT and tumour dissemination. These findings provide mechanistic insight into CAF-tumour cell crosstalk and highlight actionable stromal targets for anti-metastatic therapies across diverse malignancies.


  • Open Access

    Correction: CLPTM1L interacts with ERLIN2 to stabilize SREBP1 and drive tumorigenesis in nasopharyngeal carcinoma

    by Jian Zhang, Shu-Qiang Liu, Xiang-Yu Xiong, Ya-Qing Zhou, Pan-Pan Wei, Xin-Yuan Guan, Jin-Xin Bei, Qian Cui, Chun-Ling Luo

  • Open Access

    CLPTM1L interacts with ERLIN2 to stabilize SREBP1 and drive tumorigenesis in nasopharyngeal carcinoma

    by Jian Zhang, Shu-Qiang Liu, Xiang-Yu Xiong, Ya-Qing Zhou, Pan-Pan Wei, Xin-Yuan Guan, Jin-Xin Bei, Qian Cui, Chun-Ling Luo

    CLPTM1L has been identified as a susceptibility gene associated with nasopharyngeal carcinoma (NPC) risk, but its biological function and underlying mechanisms remain unclear. Here, we demonstrate that CLPTM1L is highly expressed in NPC patients and is associated with poor prognosis. Functional assays reveal that CLPTM1L overexpression significantly enhances NPC cell proliferation, migration and invasion, whereas its knockdown induces apoptosis and suppresses tumor growth. We further uncover that the transcription factor KLF1 directly binds to the promoter of CLPTM1L, driving its transcriptional activation. Transcriptome analysis indicates that CLPTM1L regulates various lipid metabolic pathways, notably upregulating SREBP1, a key metabolic regulator, thereby increasing intracellular free fatty acid levels in NPC cells. Mechanically, CLPTM1L interacts with the lipid raft-associated protein ERLIN2 to cooperatively stabilize SREBP1 protein levels by inhibiting its ubiquitination. Furthermore, knockdown of either ERLIN2 or SREBP1 remarkably inhibits the proliferation and migration capabilities of NPC cells, synergizing with CLPTM1L depletion. Importantly, SREBP1 overexpression markedly restored the inhibitory effects mediated by CLPTM1L and ERLIN2 knockdown, underscoring SREBP1 as a critical mediator in CLPTM1L’s oncogenic role. These findings delineate a novel pathogenic mechanism in NPC, highlighting the KLF1/CLPTM1L/ERLIN2/SREBP1 regulatory cascade as a promising therapeutic target for NPC treatment.


  • Open Access

    Epstein-Barr virus hijacks histone demethylase machinery to drive epithelial malignancy progression through KDM5B upregulation

    by Ya-Qing Zhou, Jia-Xin Jiang, Shuai He, Yi-Qi Li, Xi-Xi Cheng, Shu-Qiang Liu, Pan-Pan Wei, Xin-Yuan Guan, Choon Kiat Ong, Vivien Ya-Fan Wang, et al.

    Epstein-Barr virus (EBV) is a significant epigenetic driver in the development of epithelial-origin nasopharyngeal carcinoma (NPC) and gastric cancer (GC), which together represent 80% of EBV-associated malignancies. Despite its known association, the specific mechanisms, particularly those involving EBV-induced histone modifications, remain poorly understood. Through integrative analyses of single-cell and bulk transcriptome data from epithelial tumor tissues and EBV-infected cells, we identified KDM5B as a critical histone-modifying factor consistently upregulated following EBV infection. We demonstrated that EBV stimulates KDM5B expression via interactions of its latent gene EBNA1 with transcription factor CEBPB and through direct binding of its lytic gene BZLF1 to Zta-response elements on the KDM5B promoter. Functional assays revealed that KDM5B acts as an oncogene, correlating with poor survival outcomes in EBV-associated epithelial cancers. Mechanistically, KDM5B inhibited the tumor suppressor gene PLK2 through histone demethylation, thereby activating the PI3K/AKT/mTOR signaling pathway and promoting malignant progression. Furthermore, treatment with the KDM5B inhibitor AS-8351 markedly attenuated this signaling activity and exhibited strong anti-tumor effect in both in vitro and in vivo patient-derived xenograft models from EBV-associated tumors. Together, these findings provide novel insights into how EBV hijacks KDM5B to mediate histone demethylation of PLK2, facilitating tumor progression through the PI3K/AKT/mTOR pathway in epithelial cancers, highlighting promising therapeutic strategies targeting epigenetic alterations in EBV-associated cancers.


  • Open Access

    Super-enhancer–driven EFNA1 fuels tumor progression in cervical cancer via the FOSL2-Src/AKT/STAT3 axis

    by Shu-Qiang Liu, Xi-Xi Cheng, Shuai He, Tao Xia, Yi-Qi Li, Wan Peng, Ya-Qing Zhou, Zi-Hao Xu, Mi-Si He, Yang Liu, et al.

    Super-enhancers (SEs) are expansive cis -regulatory elements known for amplifying oncogene expression across various cancers. However, their role in cervical cancer (CC), a remarkable global malignancy affecting women, remains underexplored. Here we applied integrated epigenomic and transcriptomic profiling to delineate the distinct SE landscape in CC by analyzing paired tumor and normal tissues. Our study identifies a tumor-specific SE at the EFNA1 locus that drives EFNA1 expression in CC. Mechanically, the EFNA1-SE region contains consensus sequences for the transcription factor FOSL2, whose knockdown markedly suppressed luciferase activity and diminished H3K27ac enrichment within the SE region. Functional analyses further underlined EFNA1’s oncogenic role in CC, linking its overexpression to poor patient outcomes. EFNA1 knockdown strikingly reduced CC cell proliferation, migration, and tumor growth. Moreover, EFNA1 cis -interacted with its receptor EphA2, leading to decreased EphA2 tyrosine phosphorylation and subsequent activation of the Src/AKT/STAT3 forward signaling pathway. Inhibition of this pathway with specific inhibitors substantially attenuated the tumorigenic capacity of EFNA1-overexpressing CC cells in both in vitro and in vivo models. Collectively, our study unveils the critical role of SEs in promoting tumor progression through the FOSL2-EFNA1-EphA2-Src/AKT/STAT3 axis, providing new prognostic and therapeutic avenues for CC patients.


  • Top Cited Papers
    Open Access

    Whole-exome sequencing association study reveals genetic effects on tumor microenvironment components in nasopharyngeal carcinoma

    by Yanni Zeng, Chun-Ling Luo, Guo-Wang Lin, Fugui Li, Xiaomeng Bai, Josephine Mun-Yee Ko, Lei Xiong, Yang Liu, Shuai He, Jia-Xin Jiang, et al.

    Nasopharyngeal carcinoma (NPC) presents a substantial clinical challenge due to the limited understanding of its genetic underpinnings. Here we conduct the largest scale whole-exome sequencing association study of NPC to date, encompassing 6,969 NPC cases and 7,100 controls. We unveil 3 germline genetic variants linked to NPC susceptibility: a common rs2276868 in RPL14 , a rare rs5361 in SELE , and a common rs1050462 in HLA-B . We also underscore the critical impact of rare genetic variants on NPC heritability and introduce a refined composite polygenic risk score (rcPRS), which outperforms existing models in predicting NPC risk. Importantly, we reveal that the polygenic risk for NPC is mediated by EBV infection status. Utilizing a comprehensive multiomics approach that integrates both bulk-transcriptomic ( n = 356) and single-cell RNA sequencing ( n = 56) data with experimental validations, we demonstrate that the RPL14 variant modulates the EBV life cycle and NPC pathogenesis. Furthermore, our data indicate that the SELE variant contributes to modifying endothelial cell function, thereby facilitating NPC progression. Collectively, our study provides crucial insights into the intricate genetic architecture of NPC, spotlighting the vital interplay between genetic variations and tumor microenvironment components, including EBV and endothelial cells, in predisposing to NPC. This study opens new avenues for advancements in personalized risk assessments, early diagnosis, and targeted therapies for NPC.


  • Open Access

    A rare KLHDC4 variant Glu510Lys is associated with genetic susceptibility and promotes tumor metastasis in nasopharyngeal carcinoma

    by Xi-Xi Cheng, Guo-Wang Lin, Ya-Qing Zhou, Yi-Qi Li, Shuai He, Yang Liu, Yan-Ni Zeng, Yun-Miao Guo, Shu-Qiang Liu, Wan Peng, et al.


  • Identification of novel germline mutations in FUT7 and EXT1 linked with hereditary multiple exostoses

    by Wan Peng, Gao-Fei Li, Guo-Wang Lin, Xi-Xi Cheng, Xiao-Yu Zuo, Qiao-Hong Lin, Shu-Qiang Liu, De-Jun Li, Dao-Chao Lin, Jun-Qiang Yin, et al.

    Hereditary multiple exostoses (HME) is an autosomal dominant skeletal disorder primarily linked with mutations in Exostosin-1 (EXT1) and Exostosin-2 (EXT2) genes. However, not all HME cases can be explained by these mutations, and its pathogenic mechanisms are not fully understood. Herein, utilizing whole-exome sequencing and genetic screening with a family trio design, we identify two novel rare mutations co-segregating with HME in a Chinese family, including a nonsense mutation (c.204G>A, p.Trp68*) in EXT1 and a missense mutation (c.893T>G, p.Phe298Cys) in FUT7. Functional assays reveal that the FUT7 mutation affects the cellular localization of FUT7 protein and regulates cell proliferation. Notably, the simultaneous loss of fut7 and ext1 in a zebrafish model results in severe chondrodysplasia, indicating a functional link between FUT7 and EXT1 in chondrocyte regulation. Additionally, we unveil that FUT7 p.Phe298Cys reduces EXT1 expression through IL6/STAT3/SLUG axis at the transcription level and through ubiquitination-related proteasomal degradation at the protein level. Together, our findings not only identify novel germline mutations in FUT7 and EXT1 genes, but also highlight the critical interaction between these genes, suggesting a potential ‘second-hit’ mechanism over EXT1 mutations in HME pathogenesis. This insight enhances our understanding of the mechanisms underlying HME and opens new avenues for potential therapeutic interventions.

  • Top Cited Papers
    Open Access

    Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal carcinoma

    by Yang Liu, Shuang-Yan Ye, Shuai He, Dong-Mei Chi, Xiu-Zhi Wang, Yue-Feng Wen, Dong Ma, Run-Cong Nie, Pu Xiang, You Zhou, et al.

    Tertiary lymphoid structures are immune cell aggregates linked with cancer outcomes, but their interactions with tumour cell aggregates are unclear. Using nasopharyngeal carcinoma as a model, here we analyse single-cell transcriptomes of 343,829 cells from 77 biopsy and blood samples and spatially-resolved transcriptomes of 31,316 spots from 15 tumours to decipher their components and interactions with tumour cell aggregates. We identify essential cell populations in tertiary lymphoid structure, including CXCL13+ cancer-associated fibroblasts, stem-like CXCL13+CD8+ T cells, and B and T follicular helper cells. Our study shows that germinal centre reaction matures plasma cells. These plasma cells intersperse with tumour cell aggregates, promoting apoptosis of EBV-related malignant cells and enhancing immunotherapy response. CXCL13+ cancer-associated fibroblasts promote B cell adhesion and antibody production, activating CXCL13+CD8+ T cells that become exhausted in tumour cell aggregates. Tertiary lymphoid structure-related cell signatures correlate with prognosis and PD-1 blockade response, offering insights for therapeutic strategies in cancers.